Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33731
Title: Follicle-stimulating hormone is required for the initial phase of spermatogenic restoration in adult rats following gonadotropin suppression.
Authors: Stanton P.G.;McLachlan R.I.;Robertson D.M.;Meachem S.J.;Wreford N.G.
Institution: (Meachem, Stanton, Robertson, McLachlan) Prnc. Henry's Inst. of Med. Research, Monash Medical Centre, Monash University, Clayton, Vic., Australia (Wreford) Inst. of Repro. and Development, Monash Medical Centre, Monash University, Clayton, Vic., Australia (McLachlan) Prnc. Henry's Inst. of Med. Research, 252 Clayton Road, Clayton, Vic. 3168, Australia
Issue Date: 19-Oct-2012
Copyright year: 1998
Publisher: American Society of Andrology Inc. (74 New Montgomery, Suite 230, San Francisco CA 94105, United States)
Place of publication: United States
Publication information: Journal of Andrology. 19 (6) (pp 725-735), 1998. Date of Publication: 1998.
Abstract: The role of follicle-stimulating hormone (FSH) in adult rat spermatogenesis is unclear. Although exogenous testosterone (T) restores spermatogenesis following gonadotropin-releasing hormone (GnRH) immunization or T plus estradiol (TE) treatments, an assessment of the independent action of T and FSH was not possible, as exogenous T treatment maintains serum FSH levels. We have used passive immunization against FSH to determine whether T alone is capable of reinitiating spermatogenesis after chronic and acute FSH withdrawal. Adult rats received T-filled Silastic implants 6 cm (T6) or 8 cm (T24) in length for 7 days in combination with either a polyclonal sheep antisera raised against rat FSH (FSHAb, 2 mg/kg SC daily) or control sheep immunoglobulin (ConAb) after either GnRH immunization (12 weeks) or TE treatment (9 weeks). The neutralizing capacity of the FSHAb was determined using a FSH in vitro bioassay; this analysis demonstrated that administration of FSHAb in vivo reduced FSH levels by >90%. Testes were fixed and germ cell number per testis quantified using the optical dissector. GnRH immunization reduced spermatogonia, pachytene spermatocytes, and round spermatids to 50, 13, and <1% of normal, respectively. T6 and T24 Silastic implants with the inclusion of the FSHAb did not increase the number of spermatogonia, pachytene spermatocytes, and round spermatids (50, 15, and 1% of normal, respectively). T6+ConAb treatment increased spermatogonial, pachytene spermatocyte, and round spermatid numbers to 74, 30, and 3% of normaL, respectively (P < 0.05). No further increases were seen with T24 implants. TE treatment suppressed pachytene spermatocytes and round spermatids to 33 and 1% of normal, respectively (P < 0.05). T6+FSHAb treatment did not increase the number of pachytene spermatocytes and round spermatids (36 and 8%, respectively), whereas T6+ConAb treatment increased pachytene spermatocyte and round spermatid number to 50 and 28% of normal, respectively (P < 0.05). T24+ FSHAb treatment increased the number of pachytene spermatocyte and round spermatids (56 and 22% of normal, respectively; P < 0.05), whereas T24+ConAb treatment increased these cells forms to 79 and 31% of normal, respectively. In conclusion, T alone is unable to restore spermatogenic cell populations in the setting of chronic FSH withdrawal. Although acute FSH withdrawal markedly impairs the restoration process, higher doses of T can partially compensate for the lack of FSH. These data suggest that FSH is important for the initial phase of spermatogenic restoration.
PubMed URL: 9876024 [http://www.ncbi.nlm.nih.gov/pubmed/?term=9876024]
ISSN: 0196-3635
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/33731
Type: Article
Appears in Collections:Articles

Show full item record

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.